cardamonin and Lymphoma--Follicular

mTORC1 (mechanistic target of rapamycin complex 1) is associated with lymphoma progression. Oncogenic RRAGC (Rag guanosine triphosphatase C) mutations identified in patients with follicular lymphoma facilitate the interaction between Raptor (regulatory protein associated with mTOR) and Rag GTPase. It promotes the activation of mTORC1 and accelerates lymphomagenesis. Cardamonin inhibits mTORC1 by decreasing the protein level of Raptor. In the present study, we investigated the inhibitory effect and possible mechanism of action of cardamonin in RRAGC-mutant lymphoma. This could provide a precise targeted therapy for lymphoma with RRAGC mutations.. Cell viability was measured using a cell counting kit-8 (CCK-8) assay. Protein expression and phosphorylation levels were determined using western blotting. The interactions of mTOR and Raptor with RagC were determined by co-immunoprecipitation. Cells overexpressing RagC wild-type (RagC. Cardamonin disrupted mTOR complex interactions by decreasing Raptor protein levels. RagC. Cardamonin exerts selective therapeutic effects on RagC

Topics: Animals; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Mechanistic Target of Rapamycin Complex 1; Monomeric GTP-Binding Proteins; Regulatory-Associated Protein of mTOR; TOR Serine-Threonine Kinases